Displaying 1 - 12 of 20
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
5

Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022

View
Metabolism, Alcohol & Toxicity
5

Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022

View
Metabolism, Alcohol & Toxicity
5

Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022

View
Metabolism, Alcohol & Toxicity
5

Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022

View
Metabolism, Alcohol & Toxicity
6

Perspectum: Advances in non-invasive imaging for NAFLD / NASH - ILC 2022

View
Metabolism, Alcohol & Toxicity
6

Perspectum: Advances in non-invasive imaging for NAFLD / NASH - ILC 2022

View
Displaying 1 - 12 of 20